Non-FDA Approved Treatments: What "Legal to Offer" Doesn't Tell You About Advertising It

For physicians and medical practice owners working in regenerative medicine, one of the more frustrating parts of digital marketing is the gap between what you're legally allowed to provide to your patients and what you're allowed to advertise on major platforms like Google and Meta.

This comes up constantly with practices offering platelet-rich plasma (PRP), stem cell therapies, exosome-based treatments, and other non-surgical approaches to medical aesthetics, wellness, orthopedic, spinal, and pain-related conditions. A physician may be fully licensed to offer a treatment under state law, yet still find that Google or Meta won't allow paid campaigns promoting it.

At first glance, that can feel arbitrary. If a treatment is legal in the state, and a doctor has seen real results in their own patients, why should an ad platform get a say? The answer comes down to three separate systems that all touch this space but don't operate the same way, and don't always agree.

State law determines what a licensed physician may provide, and it varies meaningfully from state to state. This is one area where a practice should always confirm its own state's specifics rather than assume, since regenerative medicine regulation is still evolving in a lot of jurisdictions.

Federal regulation, primarily through the FDA, is a separate layer. The FDA can regulate a product or therapy nationwide without having approved it for a specific use or condition. "FDA-regulated" and "FDA-approved" get used interchangeably, but they aren't the same thing, and that distinction matters more than most practices realize. A treatment can fall under FDA oversight without being approved for a specific medical use. For regenerative medicine and wellness practices, confusing those two terms or misrepresenting their approval status with the FDA can lead to compliance problems.

Advertising policy, set independently by companies like Google and Meta, is the third layer. These platforms aren't government agencies, and they're not obligated to allow every legally available treatment to be promoted through their systems. A practice can be legally cleared to offer a treatment and still run into a flat "we don't permit this category of ad" from a platform that has nothing to do with state licensing boards or the FDA.

Put simply: legal to offer doesn't automatically mean legal, or permitted, to advertise.

It's tempting to read this as tech companies being overly cautious or covering themselves. There's some of that, but the bigger issue is that medical advertising carries a different risk profile than most other categories.

If someone sees an ad for a restaurant and has a bad meal, the fallout is limited. If a patient sees an ad for a medical treatment, acts on it, and has a serious adverse outcome, the consequences run deeper: physical harm, delayed diagnosis, financial loss, or a patient choosing an unproven therapy over a more established one. 

Platforms that allow millions of advertisers to reach billions of users can't realistically have a physician review every regenerative medicine ad before it goes live, so they build broad policies instead. Those policies are primarily enforced by automated computer systems and AI tools that rapidly scan ads, websites, landing pages, images, videos, and keywords for content that may violate their advertising rules. These systems are built to evaluate enormous volumes of ads in seconds, not to make nuanced medical judgments, so they often err on the side of caution and flag content even when the underlying claims are accurate. As a result, advertising a treatment that is not FDA-approved for its promoted use can do more than just cause a single ad to be rejected. It can trigger Google's or Meta's automated policy enforcement systems to flag or suspend your entire advertising account, and once an account is suspended, every ad running under it stops, not just the one that triggered the review." That can disrupt one of your practice's most important sources of new patient inquiries.

Unfortunately, those policies end up applying evenly to responsible providers and less careful ones alike, which is part of why the restrictions can feel disproportionate to a practice that's operating well within the lines.

There's also a real gap in what patients understand. Someone dealing with chronic back pain or a lingering sports injury may see an ad claiming a treatment can "repair damaged tissue" or "eliminate chronic pain" and read that as proof the treatment is established and proven, when the reality is more layered. A treatment can be promising without being conclusively proven, and a physician can have strong patient outcomes without that rising to the required level of large-scale clinical evidence. 

Platforms are, in part, trying to close that information gap before it turns into harm.

The practical takeaway is that "we can legally offer it" and "we can run a Google or Meta ad promoting it" are two separate questions. A yes to the first doesn't guarantee a yes to the second. It's worth walking through both, along with whether the specific wording of an ad and its landing page comply with a specific advertising platform’s policy, since that's often where campaigns get flagged, even when the underlying treatment is entirely legitimate.

None of this means a practice is stuck. Instead of trying to advertise a restricted treatment directly, many practices shift the marketing focus to the broader area of care: wellness treatments, non-surgical spine care, sports injury treatment, interventional pain management, orthopedic consultations. From there, the website and educational content can go deeper, laying out treatment options, current evidence, and what a consultation actually involves, as long as everything stays within applicable laws and platform guidelines.

That shift in strategy opens the door for SEO, AI optimization, physician expertise, and organic visibility to do more of the heavy lifting. 

Rather than an ad that promises a specific outcome, a practice can build out real educational resources that walk through the differences between treatment options and what the evidence currently supports. It's a slower path than a paid ad, but it tends to hold up better over time, and it builds the kind of credibility that a restricted ad campaign never could.

The regulatory picture here is complicated, and it's not something to navigate off a single article. Every state has its own rules, every platform updates its policies on its own timeline, and specific guidance should come from qualified legal counsel alongside your marketing team. What's consistent across all of it is this: understanding where these systems overlap, and where they don't, is what lets a practice build a strategy that actually holds up, instead of running into walls it didn't see coming.

oOo